TMCnet News
Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines AgencyVANCOUVER, British Columbia, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in a subset of patients with partial lipodystrophy (PL). The MAA was filed in December 2016. An opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in December of 2017, and decision is expected in the first quarter of 2018. “The MAA filing acceptance marks important progress in our priority initiative to deliver MYALEPTA® to adult and pediatric GL and a subset of PL patients in Europe,” said John Orloff, M.D., executive vice president, head of research and development for Novelion Therapeutics. “There are more than 100 patients on therapy via a pre-approval compassionate use program in certain markets in Europe, the majority of whom are within the proposed indications. Additionally, there are a meaningful number of patients who currently have limited options for treating complications of these rare forms of lipodystrophy. We look forward to working with European regulatory authorities with the objective of achieving marketing authorization and bringing this needed therapy to patients.” Metreleptin was granted orphan drug designation by the European Commission in July 2012, and, if approved, will carry 10 years of orphan drug exclusivity in the EU. The company estimates the prevalence of GL is approximately one in one million people, and the prevalence of the subset of PL being targeted for approval is approximately one half to one in one million people. The company, through a subsidiary, will seek to market metreleptin in the EU, if approved, under the tradename MYALEPTA. U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION MYALEPT® (metreleptin) for injection is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. LIMITATIONS OF USE: The safety and effectiveness of MYALEPT for the treatmentof complications of partial lipodystrophy or for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established. Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with MYALEPT. For more detailed information, please see additional Important Safety Information and the Prescribing Information for MYALEPT. Forward Looking Statements: For additional disclosure regarding these and other risks we face, see the disclosure contained in the "Risk Factors" section of Aegerion's Quarterly Report on Form 10-Q filed on November 4, 2016, Novelion’s Annual Report on Form 10-K filed on February 25, 2016 (and amended on April 29, 2016) and Quarterly Report on Form 10-Q filed on November 1, 2016 and each company’s other public filings with the SEC, available on the SEC's website at www.sec.gov. Except as required by law, we undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Investors and others should note that we communicate with our investors and the public using our company website www.novelion.com, including, but not limited to, company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference calls transcripts and webcast transcripts. The information that we post on these websites could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected] |